Campbell Bradley L 4

What Happened Bradley L. Campbell, President, CEO and Director of Amicus Therapeutics (FOLD), exercised 75,000 stock options and immediately sold 75,000 resulting shares on January 20, 2026. The options were exercised at $6.10 per share (total exercise cost $457,500) and the open-market sale fetched a weighted average price of $14.31 per share for proceeds of approximately $1,073,183. The filing also reports the related derivative instrument disposition reflecting the conversion of the options.

Key Details

• Transaction date: January 20, 2026; Form 4 filed January 22, 2026 (timely).
• Exercise: 75,000 shares exercised at $6.10/share = $457,500 (code M).
• Sale: 75,000 shares sold in open market at weighted avg $14.31/share = $1,073,183 (prices ranged $14.30–$14.32; see footnote).
• Derivative line: 75,000-option derivative shown as disposed at $0 to reflect conversion.
• Footnotes: Options were fully vested and exercisable as of the transaction date (F2). Sale price is a weighted average; detailed per-price breakdown available on request (F1).
• Plan: All transactions were made pursuant to a Rule 10b5-1 trading plan adopted Sept 12, 2025 (remark).
• Shares owned after transaction: not disclosed in this filing.

Context This was an options exercise followed by an immediate sale of the shares—commonly a cashless exercise where the insider converts options to stock and sells the shares the same day. The activity was executed under a pre-established 10b5-1 plan, which is often used to schedule trades in advance and reduce concerns about trading on undisclosed information. The filing is factual and does not indicate the insider’s motivation.